Panorama® prenatal screening

Because knowledge is reassuring

Information for healthcare professionals

This page contains information for healthcare professionals who are interested in offering the Panorama test to their patients.  Information for pregnant women who are interested in the test can be found on the information for pregnant women page.

The Panorama Prenatal screening test, now available in partnership with NewGene Ltd, is an innovative non-invasive prenatal test (NIPT) that analyses fetal-placental, cell-­free DNA isolated from maternal plasma. Panorama offers highly accurate, comprehensive panels to screen for fetal aneuploidies and microdeletion syndromes.

Safe and accurate

Non-invasive prenatal testing (NIPT) can prompt a diagnostic journey that gives families time to prepare for the birth of a child with a genetic disorder.  ACMG recommends that women of all ages be informed that NIPT is the most sensitive screening test for traditionally screened aneuploidies, including Down's syndrome, a position which is also supported by the International Society for Prenatal Diagnosis. While the prevalence of some conditions, such as Down's syndrome, increases with maternal age, microdeletions occur randomly, meaning women of all ages are at equal risk. Panorama NIPT is highly accurate when compared to maternal serum screening and it poses no risk of miscarriage, unlike diagnostic procedures such as amniocentesis.

What is Panorama®?

Panorama is a non-invasive DNA screening test that can give your patients important information about their pregnancy, as early as nine weeks of gestation. Panorama is a proven and market-leading test, with over 600,000 tests performed on patients from 60 countries.  The methodology employed by the test gives the lowest combined false-negative rate of any NIPT currently on the market and zero errors in fetal sex determination in validation studies.

Panorama incorporates maternal age and fetal fraction into the calculation of every risk score and includes fetal fraction on every report.  Only samples which meet the test quality metrics are reported upon.
The observed no-call rate in clinical experience is 4%.

What Panorama® screens for

Panorama is the only non-invasive prenatal screening test that distinguishes between fetal and maternal cell-free DNA thanks to SNP-based sequencing and Natera's proprietary algorithm. Using advanced bioinformatics techniques, Panorama screens for a broad panel of chromosomal conditions, including:

Chromosome Abnormalities:

  • Trisomy 21 (Down’s syndrome) >99.9% sensitivity (83/83);
    False positive rate 0%
  • Trisomy 18 (Edwards’ syndrome) >96.4% sensitivity (27/28);
    False positive rate <0.1%
  • Trisomy 13 (Patau syndrome) >99.9% sensitivity (13/13);
    False positive rate 0%
  • Triploidy >99.9% sensitivity (8/8);
    False postive rate 0%

Sex Chromosome Abnormalities:

  • Monosomy X (Turner’s syndrome) >92.9% sensitivity (13/14);
    False positive rate <0.1%
  • Klinefelter syndrome >99.9% sensitivity
  • Triple X syndrome >99.9% sensitivity
  • XYY syndrome >99.9% sensitivity

Microdeletions:

  • 22q11.2 deletion syndrome >95.7% sensitivity (45/47)
  • 1p36 deletion syndrome >93.8% - >99% sensitivity
  • Prader Willi syndrome >93.8% - >99% sensitivity
  • Angelman syndrome >93.8% - >99% sensitivity
  • Cri-du-chat syndrome >93.8% - >99% sensitivity

Currently, Panorama cannot be used in the following types of pregnancies:

  • Multiple gestation pregnancies
  • Pregnancies that are using a donor egg or a surrogate
  • Pregnant women who are bone marrow transplant recipients

The advantages of the Panorama® SNP-based method

Panorama is the only commercially available NIPT that specifically analyses single nucleotide polymorphisms (SNPs) to determine chromosome copy number. Validated at fetal fractions as low as 2.8%, this approach sequences cell-free DNA from maternal plasma to infer the fetal genotype. Panorama targets 13,392 SNPs covering chromosomes 21, 18, 13, X, and Y; additional sets of SNPs are targeted for identification of microdeletions. A patented algorithm is then used to determine the chance of fetal chromosome abnormalities and identify fetal sex (when requested).

The ability to differentiate between maternal and fetal placental DNA also enables Panorama to identify the presence of a vanishing twin and to minimise false positives due to maternal abnormalities. Panorama is also uniquely able to identify triploidy and complete molar pregnancies.

Compared to competitor NIPT assays, Panorama has several advantages, with the lowest false negative rate (0.6% in published clinical trials), highest sensitivity for 22q11.2 deletion syndrome and zero errors in fetal sex determination in validation studies.

For further details comparing Panorama with other NIPT assays, please consult the 'Why choose Panorama' section of the Natera website.

Offer Panorama® to your patients

To obtain Panorama sample collection kits, please contact NewGene Ltd (UK and Republic of Ireland only).

email:  info@newgene.org.uk

Telephone:  0191 242 1923

Panorama NIPT is highly accurate when compared to maternal serum screening and it poses no risk of miscarriage

NewGene Ltd

Bioscience Building, International Centre for Life, Newcastle upon Tyne, NE1 4EP, UK
Tel: +44 (0)191 242 1923 | Fax: +44 (0)191 241 8799 | Email: info@newgene.org.uk | Web:www.newgene.org.uk

Š NewGene Limited | Company Number: 06735445

NewGene partners